#### Edgar Filing: PROVECTUS BIOPHARMACEUTICALS, INC. - Form 4

#### PROVECTUS BIOPHARMACEUTICALS, INC.

Form 4

January 09, 2017

### FORM 4

Check this box

if no longer

subject to

Section 16.

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES** 

Form 4 or Form 5 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. 30(h) of the Investment Company Act of 1940 See Instruction

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person \* 5. Relationship of Reporting Person(s) to 2. Issuer Name and Ticker or Trading CULPEPPER PETER R Issuer Symbol **PROVECTUS** (Check all applicable) BIOPHARMACEUTICALS, INC. [PVCT] Director 10% Owner \_\_X\_\_ Other (specify Officer (give title (Last) (First) (Middle) 3. Date of Earliest Transaction below) below) (Month/Day/Year) Prior Interim CEO, CFO, COO P.O. BOX 32429 12/28/2016 (Street) 4. If Amendment, Date Original 6. Individual or Joint/Group Filing(Check Filed(Month/Day/Year) Applicable Line) \_X\_ Form filed by One Reporting Person Form filed by More than One Reporting KNOXVILLE, TN 37930 Person (State) (City) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of 2. Transaction Date 2A. Deemed 4. Securities 5. Amount of 6. Ownership 7. Nature of Security (Month/Day/Year) Execution Date, if TransactionAcquired (A) or Securities Form: Direct Indirect (Instr. 3) Disposed of (D) Beneficially Beneficial Code (D) or (Instr. 8) (Instr. 3, 4 and 5) Owned Indirect (I) Ownership (Month/Day/Year) Following (Instr. 4) (Instr. 4) Reported (A) Transaction(s) or (Instr. 3 and 4) Code V Amount (D) Price Common 1,411,829 D Stock Common By 401(k) Ι 296,503 Stock plan

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

**OMB APPROVAL** 

3235-0287

January 31,

2005

0.5

OMB

Number:

Expires:

response...

Estimated average

burden hours per

### Edgar Filing: PROVECTUS BIOPHARMACEUTICALS, INC. - Form 4

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

8. P Der Sec (Ins

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. orNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)			7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (Right to buy)	\$ 1					07/22/2010	07/22/2020	Common Stock	550,000
Share Option (Right to buy)	\$ 0.93					09/06/2011	09/06/2021	Common Stock	550,000
Share Option (Right to buy)	\$ 0.75					12/09/2015	12/09/2025	Common Stock	400,000
Warrant (Right to buy)	\$ 0.85					03/29/2016	06/19/2020	Common Stock	266,666

# **Reporting Owners**

Reporting Owner Name / Address			Rel	ationships
		10~	0.00	

Director 10% Owner Officer Other

CULPEPPER PETER R P.O. BOX 32429 KNOXVILLE, TN 37930

Prior Interim CEO, CFO, COO

## **Signatures**

/s/ Peter R. 01/09/2017 Culpepper

\*\*Signature of Date
Reporting Person

Reporting Owners 2

### Edgar Filing: PROVECTUS BIOPHARMACEUTICALS, INC. - Form 4

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

#### **Remarks:**

On December 28, 2016, the reporting person, Peter Culpepper, was terminated as an officer and an interim officer of Provectu Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.